RMP-7 drug delivery system with carboplatin data

ALKS (Cambridge, Mass.) completed three Phase I/II studies of RMP-7, a molecule that increases permeability of the blood-brain barrier, in combination with carboplatin.

At the Hambrecht & Quist Life Sciences Conference in San Francisco, the company reported no toxicity in two trials, one in the U.S. and one in the U.K. A total of 23 patients with recurrent glioma were enrolled in the trials. ...